Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Perioperative THR-184 and AKI after Cardiac Surgery.

Himmelfarb J, Chertow GM, McCullough PA, Mesana T, Shaw AD, Sundt TM, Brown C, Cortville D, Dagenais F, de Varennes B, Fontes M, Rossert J, Tardif JC.

J Am Soc Nephrol. 2018 Feb;29(2):670-679. doi: 10.1681/ASN.2017020217. Epub 2017 Dec 4.

2.

The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease.

Pollock C, Zuk A, Anders HJ, Ganji MR, Johnson DW, Kasiske B, Langham RG, Pecoits-Filho R, Remuzzi G, Rossert J, Suzuki Y, Tanaka T, Walker R, Yang CW, Bonventre JV.

Kidney Int Suppl (2011). 2017 Oct;7(2):130-137. doi: 10.1016/j.kisu.2017.07.008. Epub 2017 Sep 20. Review.

3.

Genetic and environmental risk factors for chronic kidney disease.

Obrador GT, Schultheiss UT, Kretzler M, Langham RG, Nangaku M, Pecoits-Filho R, Pollock C, Rossert J, Correa-Rotter R, Stenvinkel P, Walker R, Yang CW, Fox CS, Köttgen A.

Kidney Int Suppl (2011). 2017 Oct;7(2):88-106. doi: 10.1016/j.kisu.2017.07.004. Epub 2017 Sep 20. Review.

4.

Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics.

Vogl FC, Mehrl S, Heizinger L, Schlecht I, Zacharias HU, Ellmann L, Nürnberger N, Gronwald W, Leitzmann MF, Rossert J, Eckardt KU, Dettmer K, Oefner PJ; GCKD Study Investigators.

Anal Bioanal Chem. 2016 Nov;408(29):8483-8493. Epub 2016 Nov 4.

PMID:
27815612
5.

Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia.

Bello NA, Pfeffer MA, Skali H, McGill JB, Rossert J, Olson KA, Weinrauch L, Cooper ME, de Zeeuw D, Rossing P, McMurray JJ, Solomon SD.

BMJ Open Diabetes Res Care. 2014 Apr 6;2(1):e000011. doi: 10.1136/bmjdrc-2013-000011. eCollection 2014.

6.

Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test.

Fan L, Inker LA, Rossert J, Froissart M, Rossing P, Mauer M, Levey AS.

Nephrol Dial Transplant. 2014 Jun;29(6):1195-203. doi: 10.1093/ndt/gft509. Epub 2014 Jan 20.

7.

Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation.

Leffell MS, Kim D, Vega RM, Zachary AA, Petersen J, Hart JM, Rossert J, Bradbury BD.

Transplantation. 2014 Mar 15;97(5):525-33. doi: 10.1097/01.tp.0000437435.19980.8f.

PMID:
24300013
8.

Risk of pure red cell aplasia in patients with hepatitis C receiving antiviral therapy and an erythropoiesis-stimulating agent.

Rossert J, Yue S, Smirnakis K, Mytych DT, Johnson L, Kouchakji E, Casadevall N.

Clin Gastroenterol Hepatol. 2014 Feb;12(2):341-5. doi: 10.1016/j.cgh.2013.09.065. Epub 2013 Oct 9.

PMID:
24120841
9.

Sensitization from transfusion in patients awaiting primary kidney transplant.

Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, Rossert J, Chertow GM, Tyan DB.

Nephrol Dial Transplant. 2013 Nov;28(11):2908-18. doi: 10.1093/ndt/gft362. Epub 2013 Sep 5.

10.

Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.

Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P.

Am J Kidney Dis. 2013 Feb;61(2):238-46. doi: 10.1053/j.ajkd.2012.08.043. Epub 2012 Nov 16.

PMID:
23159232
11.

EGR1 and EGR2 involvement in vertebrate tendon differentiation.

Lejard V, Blais F, Guerquin MJ, Bonnet A, Bonnin MA, Havis E, Malbouyres M, Bidaud CB, Maro G, Gilardi-Hebenstreit P, Rossert J, Ruggiero F, Duprez D.

J Biol Chem. 2011 Feb 18;286(7):5855-67. doi: 10.1074/jbc.M110.153106. Epub 2010 Dec 20.

12.

Erythropoietic response and outcomes in kidney disease and type 2 diabetes.

Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators.

N Engl J Med. 2010 Sep 16;363(12):1146-55. doi: 10.1056/NEJMoa1005109.

13.

Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE.

Leport C, Bouteloup V, Rossert J, Garré M, Iordache L, Dellamonica P, Herson S, Raffi F, Chêne G.

Clin Infect Dis. 2009 Dec 15;49(12):1950-4. doi: 10.1086/648445.

PMID:
19911986
14.

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU.

N Engl J Med. 2009 Nov 5;361(19):1848-55. doi: 10.1056/NEJMoa074037.

15.

Transgenic mice expressing nitroreductase gene under the control of the podocin promoter: a new murine model of inductible glomerular injury.

Macary G, Rossert J, Bruneval P, Mandet C, Bélair MF, Houillier P, Duong Van Huyen JP.

Virchows Arch. 2010 Mar;456(3):325-37. doi: 10.1007/s00428-009-0840-9. Epub 2009 Oct 6.

PMID:
19806361
16.

Timing of onset of CKD-related metabolic complications.

Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M'rad MB, Jacquot C, Houillier P, Stengel B, Fouqueray B; NephroTest Study Group.

J Am Soc Nephrol. 2009 Jan;20(1):164-71. doi: 10.1681/ASN.2008020159. Epub 2008 Nov 12.

17.

Epoetin-associated pure red cell aplasia: past, present, and future considerations.

McKoy JM, Stonecash RE, Cournoyer D, Rossert J, Nissenson AR, Raisch DW, Casadevall N, Bennett CL.

Transfusion. 2008 Aug;48(8):1754-62. doi: 10.1111/j.1537-2995.2008.01749.x. Epub 2008 May 14. Review.

18.

Pitfalls of measuring total blood calcium in patients with CKD.

Gauci C, Moranne O, Fouqueray B, de la Faille R, Maruani G, Haymann JP, Jacquot C, Boffa JJ, Flamant M, Rossert J, Urena P, Stengel B, Souberbielle JC, Froissart M, Houillier P; NephroTest Study Group.

J Am Soc Nephrol. 2008 Aug;19(8):1592-8. doi: 10.1681/ASN.2007040449. Epub 2008 Apr 9.

19.

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

Stevens LA, Coresh J, Schmid CH, Feldman HI, Froissart M, Kusek J, Rossert J, Van Lente F, Bruce RD 3rd, Zhang YL, Greene T, Levey AS.

Am J Kidney Dis. 2008 Mar;51(3):395-406. doi: 10.1053/j.ajkd.2007.11.018.

20.

Primary glomerulonephritis: an update on renal survival and determinants of progression.

Moranne O, Watier L, Rossert J, Stengel B; GN-Progress Study Group.

QJM. 2008 Mar;101(3):215-24. doi: 10.1093/qjmed/hcm142. Epub 2008 Feb 2.

PMID:
18245806
21.

Pure red cell aplasia induced by erythropoiesis-stimulating agents.

Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E.

Clin J Am Soc Nephrol. 2008 Jan;3(1):193-9. doi: 10.2215/CJN.02440607. Review.

22.

Vasculitides associated with malignancies: analysis of sixty patients.

Fain O, Hamidou M, Cacoub P, Godeau B, Wechsler B, Pariès J, Stirnemann J, Morin AS, Gatfosse M, Hanslik T, Belmatoug N, Blétry O, Cevallos R, Delevaux I, Fisher E, Hayem G, Kaplan G, Le Hello C, Mouthon L, Larroche C, Lemaire V, Piette AM, Piette JC, Ponge T, Puechal X, Rossert J, Sarrot-Reynauld F, Sicard D, Ziza JM, Kahn MF, Guillevin L.

Arthritis Rheum. 2007 Dec 15;57(8):1473-80.

23.

EMEA guidelines on biosimilars and their clinical implications.

Rossert J.

Kidney Blood Press Res. 2007;30 Suppl 1:13-7. Epub 2007 Aug 27. Review. No abstract available.

24.

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes.

Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU, Nahas ME, Jaber BL, Jadoul M, Levin A, Powe NR, Rossert J, Wheeler DC, Lameire N, Eknoyan G.

Kidney Int. 2007 Aug;72(3):247-59. Epub 2007 Jun 13.

25.

New insight into solvent-related end-stage renal disease: occupations, products and types of solvents at risk.

Jacob S, Héry M, Protois JC, Rossert J, Stengel B.

Occup Environ Med. 2007 Dec;64(12):843-8. Epub 2007 Jun 13.

26.

Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts.

Léjard V, Brideau G, Blais F, Salingcarnboriboon R, Wagner G, Roehrl MH, Noda M, Duprez D, Houillier P, Rossert J.

J Biol Chem. 2007 Jun 15;282(24):17665-75. Epub 2007 Apr 12.

27.

[Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents].

Rossert J, Casadevall N.

Nephrol Ther. 2006 Sep;2 Suppl 4:S283-6. French.

PMID:
17373271
28.

[The diabetic patient: renal insufficiency like other kidney failures?].

Rossert J.

Nephrol Ther. 2006 May;2 Suppl 3:S187-9. Review. French.

PMID:
17370848
29.

[Biology of renal functions and renal insufficiency].

Cristol JP; Biologie des Fonctions Rénales et de l'Insuffisance Rénale; Société Française de Biologie Clinique, Seronie-Vivien S, Sternberg M, Cavalier E, Blanchecotte F, Hanser AM, Pieroni L, Galteau MM, Monge M, Boutten A, Desch G, Ait Djafer Z, Carlier MC, Barguil Y, Terrier N, Guerber F, Souberbielle JC, Delmas Y, Delanaye P, Panescu V, Rossert J, Fouqueray B, Houillier P, Froissart M, Lefebvre HP, Canaud B, Halimi JM.

Ann Biol Clin (Paris). 2006 Nov-Dec;64(6):608-11. French. No abstract available.

30.

Atherosclerotic renovascular disease: beyond the renal artery stenosis.

Meier P, Rossert J, Plouin PF, Burnier M.

Nephrol Dial Transplant. 2007 Apr;22(4):1002-6. Epub 2007 Jan 8. Review. No abstract available.

PMID:
17210599
31.

Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.

Rossert J, Gassmann-Mayer C, Frei D, McClellan W.

Nephrol Dial Transplant. 2007 Mar;22(3):794-800. Epub 2007 Jan 8.

PMID:
17210593
32.

Effect of organic solvent exposure on chronic kidney disease progression: the GN-PROGRESS cohort study.

Jacob S, Héry M, Protois JC, Rossert J, Stengel B.

J Am Soc Nephrol. 2007 Jan;18(1):274-81. Epub 2006 Nov 29.

33.

[New developments on diabetic nephropathy].

Rossert J, Froissart M.

Journ Annu Diabetol Hotel Dieu. 2006:239-49. Review. French. No abstract available.

PMID:
17051866
34.

Role of anemia in progression of chronic kidney disease.

Rossert J, Froissart M.

Semin Nephrol. 2006 Jul;26(4):283-9. Review.

PMID:
16949466
35.

Membranous nephropathy and cancer: Epidemiologic evidence and determinants of high-risk cancer association.

Lefaucheur C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J; GN-PROGRESS Study Group.

Kidney Int. 2006 Oct;70(8):1510-7. Epub 2006 Aug 30.

36.

Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome.

Vigneau C, Daugas E, Maury E, Sokol H, Offenstadt G, Rossert J, Guidet B.

Am J Kidney Dis. 2006 Jun;47(6):1072-4.

PMID:
16731303
37.

Effect of early correction of anemia on the progression of CKD.

Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, Frei D, McClellan WM.

Am J Kidney Dis. 2006 May;47(5):738-50.

PMID:
16632012
38.

[How to improve estimation of renal function in the elderly].

Froissart M, Rossert J.

Rev Prat. 2005 Dec 31;55(20):2223-9. Review. French.

PMID:
16519048
39.

Anemia management and chronic renal failure progression.

Rossert J, Froissart M, Jacquot C.

Kidney Int Suppl. 2005 Dec;(99):S76-81. Review.

40.

Erythropoietin-induced, antibody-mediated pure red cell aplasia.

Rossert J; Pure Red Cell Aplasia Global Scientific Advisory Board (GSAB).

Eur J Clin Invest. 2005 Dec;35 Suppl 3:95-9. Review.

PMID:
16281965
41.

Immuno-allergic interstitial nephritis related to fluindione: first biopsy proven cases.

Grimaldi D, Daugas E, Mougenot B, Rossert J, Ronco P.

Nephrol Dial Transplant. 2006 Jan;21(1):237. Epub 2005 Oct 12. No abstract available.

PMID:
16221711
42.

[Research-based progress].

Rossert J, Frimat L, Chauveau D.

Presse Med. 2005 Sep 24;34(16 Pt 2):1188-90. Review. French. No abstract available.

PMID:
16208270
43.

[Vascular nephropathies].

Jacquot C, Rossert J.

Rev Prat. 2005 Jun 15;55(11):1255-60. French. No abstract available.

PMID:
16164075
44.

Renewal of FSP1: a marker of fibrogenesis on human renal biopsies.

Bruneval P, Rossert J, Bariety J.

Kidney Int. 2005 Sep;68(3):1366-7. No abstract available.

45.

Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM, Locatelli F, Belknap SM, McKoy JM, Lyons EA, Kim B, Sharma R, Costello S, Toffelmire EB, Wells GA, Messner HA, Yarnold PR, Trifilio SM, Raisch DW, Kuzel TM, Nissenson A, Lim LC, Tallman MS, Casadevall N.

Blood. 2005 Nov 15;106(10):3343-7. Epub 2005 Aug 11.

46.

Epoetin-induced autoimmune pure red cell aplasia.

Casadevall N, Eckardt KU, Rossert J.

J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S67-9. Review.

47.

The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N.

Kidney Int. 2005 Jun;67(6):2346-53.

48.

Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, Eknoyan G.

Kidney Int. 2005 Jun;67(6):2089-100.

49.

Erythropoietin receptors: their role beyond erythropoiesis.

Rossert J, Eckardt KU.

Nephrol Dial Transplant. 2005 Jun;20(6):1025-8. Epub 2005 Apr 19. Review. No abstract available.

PMID:
15840686
50.

The new Mayo Clinic equation for estimating glomerular filtration rate.

Froissart MC, Rossert J, Houillier P.

Ann Intern Med. 2005 Apr 19;142(8):679; author reply 681. No abstract available.

PMID:
15838084

Supplemental Content

Loading ...
Support Center